

# Tanja D De Gruijl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7882080/publications.pdf>

Version: 2024-02-01

245  
papers

11,547  
citations

31976

53  
h-index

39675

94  
g-index

248  
all docs

248  
docs citations

248  
times ranked

15917  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes. <i>Haematologica</i> , 2022, 107, 655-667.	3.5	16
2	Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1101.	2.4	9
3	Tumor-educated Tregs drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche. <i>Cell Reports</i> , 2022, 38, 110447.	6.4	23
4	Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T cell reduction and effector T cell activation. <i>Science Immunology</i> , 2022, 7, .	11.9	18
5	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes CD40-Mediated Antitumor Responses in Human B-cell Malignancies. <i>Cancer Immunology Research</i> , 2021, 9, 50-61.	3.4	23
6	A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF266-104/RFAGE in Patients with Advanced Solid Malignancies. <i>Oncologist</i> , 2021, 26, e218-e229.	3.7	4
7	A Bispecific Single-Domain Antibody Boosts Autologous CD40-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 1744-1755.	7.0	28
8	Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1096.	4.1	25
9	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). <i>Clinical Cancer Research</i> , 2021, 27, 3351-3359.	7.0	143
10	Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. <i>Cancers</i> , 2021, 13, 711.	3.7	18
11	Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma. <i>Human Gene Therapy</i> , 2021, 32, 178-191.	2.7	7
12	T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A <sup>+</sup> CD141 <sup>+</sup> cDC1 and CD14 <sup>+</sup> antigen-presenting cell recruitment. , 2021, 9, e001962.		9
13	Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy. <i>Frontiers in Immunology</i> , 2021, 12, 643291.	4.8	52
14	Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. <i>Current Oncology Reports</i> , 2021, 23, 68.	4.0	12
15	Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. <i>Physiological Reports</i> , 2021, 9, e14919.	1.7	13
16	Palmitoylated antigens for the induction of anti-tumor CD8 <sup>+</sup> T cells and enhanced tumor recognition. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 315-328.	4.4	3
17	CD169 Defines Activated CD14 <sup>+</sup> Monocytes With Enhanced CD8 <sup>+</sup> T Cell Activation Capacity. <i>Frontiers in Immunology</i> , 2021, 12, 697840.	4.8	33
18	Adenovirus Armed With TNF $\alpha$ and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. <i>Frontiers in Immunology</i> , 2021, 12, 706517.	4.8	13

#	ARTICLE	IF	CITATIONS
19	Pancreatic Cancer and Immunotherapy: A Clinical Overview. <i>Cancers</i> , 2021, 13, 4138.	3.7	49
20	Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. <i>Cancers</i> , 2021, 13, 3902.	3.7	18
21	HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial. , 2021, 9, e002547.		11
22	Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 4722.	3.7	22
23	The role of transforming growth factor $\hat{I}^2$ in upper gastrointestinal cancers: A systematic review. <i>Cancer Treatment Reviews</i> , 2021, 100, 102285.	7.7	9
24	Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. <i>Oncolmmunology</i> , 2021, 10, 1954807.	4.6	17
25	Liposomal Nanovaccine Containing $\hat{I}\pm$ -Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. <i>Vaccines</i> , 2021, 9, 56.	4.4	20
26	Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth. , 2021, 9, e003623.		12
27	Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. <i>Cancers</i> , 2021, 13, 5446.	3.7	12
28	Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade. <i>Cells</i> , 2021, 10, 3233.	4.1	4
29	A Multi-Organ-on-Chip Approach to Investigate How Oral Exposure to Metals Can Cause Systemic Toxicity Leading to Langerhans Cell Activation in Skin. <i>Frontiers in Toxicology</i> , 2021, 3, 824825.	3.1	17
30	Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. <i>Radiology</i> , 2020, 294, 212-220.	7.3	90
31	In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma. <i>Oncolmmunology</i> , 2020, 9, 1708066.	4.6	5
32	Selective tumor antigen vaccine delivery to human CD169 <sup>+</sup> antigen-presenting cells using ganglioside-liposomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27528-27539.	7.1	54
33	Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway. , 2020, 8, e000761.		10
34	A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response. <i>Nature Cancer</i> , 2020, 1, 1054-1065.	13.2	21
35	Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0a€1 non-small cell lung cancer: the INCREASE trial. <i>BMC Cancer</i> , 2020, 20, 764.	2.6	18
36	Expression of Oncolytic Adenovirus-Encoded RNAi Molecules Is Most Effective in a pri-miRNA Precursor Format. <i>Molecular Therapy - Oncolytics</i> , 2020, 19, 332-343.	4.4	8

#	ARTICLE	IF	CITATIONS
37	Immune checkpoint inhibition: from molecules to clinical application. <i>Clinical and Experimental Immunology</i> , 2020, 200, 105-107.	2.6	3
38	Stereotactic ablative radiotherapy for the comprehensive treatment of 1â€³ Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. <i>BMC Cancer</i> , 2020, 20, 380.	2.6	75
39	Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188386.	7.4	67
40	Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses. <i>Frontiers in Immunology</i> , 2020, 11, 990.	4.8	27
41	High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. <i>Radiology</i> , 2020, 295, 254-272.	7.3	208
42	Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8+ T Cells and Elevated $\beta$ -Catenin Activation Compared with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3791-3802.	7.0	13
43	Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2319-2331.	4.2	20
44	Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells. <i>Clinical and Experimental Immunology</i> , 2020, 201, 145-160.	2.6	7
45	PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. <i>Frontiers in Immunology</i> , 2020, 11, 596825.	4.8	53
46	Constitutively active GSK3 $\beta$ as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression. <i>Oncolmunology</i> , 2019, 8, e1631119.	4.6	8
47	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
48	Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells. <i>Current Opinion in Chemical Biology</i> , 2019, 53, 167-172.	6.1	9
49	Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. <i>Oncolmunology</i> , 2019, 8, 1652532.	4.6	75
50	Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. <i>Cancers</i> , 2019, 11, 1266.	3.7	47
51	Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. , 2019, 7, 133.		32
52	Autologous tumor cell vaccination combined with systemic CpG-B and IFN- $\gamma$ promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1025-1035.	4.2	13
53	Unlocking the therapeutic potential of primary tumor-draining lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1681-1688.	4.2	56
54	Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. , 2019, 7, 43.		42

#	ARTICLE	IF	CITATIONS
55	Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 787-798.	4.2	2
56	Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets. <i>Theranostics</i> , 2019, 9, 5797-5809.	10.0	48
57	Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination?. <i>Chinese Clinical Oncology</i> , 2019, 8, 61-61.	1.2	18
58	Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 319-329.	4.2	11
59	The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 503-515.	4.2	26
60	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4045-4045.	1.6	20
61	From Local to Systemic Treatment: Leveraging Antitumor Immunity Following Irreversible Electroporation. , 2018, , 249-270.		4
62	A safety and immunogenicity study of immunization with hVEGF 26-104 /RFASE in cynomolgus monkeys. <i>Vaccine</i> , 2018, 36, 2025-2032.	3.8	6
63	The effects of systemic treatment with aminobisphosphonates and statins on circulating VÎ³VÎ²-T cells in patients with advanced cancer. <i>Immunobiology</i> , 2018, 223, 171-177.	1.9	4
64	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of VÎ³VÎ²-T cells. <i>Oncolmunology</i> , 2018, 7, e1375641.	4.6	61
65	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 4664.	12.8	331
66	Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1990.	4.8	29
67	Improving CLL VÎ³VÎ²-T cell fitness for cellular therapy by ex vivo activation and ibrutinib. <i>Blood</i> , 2018, 132, 2260-2272.	1.4	39
68	Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 6308-6319.	0.9	51
69	â€ˆDURVITâ€™: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment. <i>BMC Cancer</i> , 2018, 18, 888.	2.6	23
70	Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs. <i>Vaccines</i> , 2018, 6, 42.	4.4	8
71	Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1598.	4.8	31
72	A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1505-1518.	4.2	62

#	ARTICLE	IF	CITATIONS
73	CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. <i>Oncolimmunology</i> , 2018, 7, e1490856.	4.6	28
74	Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from slan+ Non-Classical Monocytes. <i>Frontiers in Immunology</i> , 2018, 9, 1619.	4.8	16
75	Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells. <i>Cellular and Molecular Immunology</i> , 2017, 14, 360-370.	10.5	37
76	Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression. <i>Clinical Cancer Research</i> , 2017, 23, 3721-3733.	7.0	150
77	Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. <i>Scientific Reports</i> , 2017, 7, 43873.	3.3	28
78	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. <i>ERJ Open Research</i> , 2017, 3, 00110-2016.	2.6	20
79	Prevention of V $\beta$ 9V $\alpha$ 2 T Cell Activation by a V $\beta$ 9V $\alpha$ 2 TCR Nanobody. <i>Journal of Immunology</i> , 2017, 198, 308-317.	0.8	9
80	Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. <i>Oncolimmunology</i> , 2017, 6, e1265717.	4.6	25
81	Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage Iâ€”II Melanoma: Data from Two Randomized Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5679-5686.	7.0	57
82	Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence. <i>Cancer Immunology Research</i> , 2017, 5, 969-977.	3.4	34
83	Immunological effects of everolimus in patients with metastatic renal cell cancer. <i>International Journal of Immunopathology and Pharmacology</i> , 2017, 30, 341-352.	2.1	21
84	Transcriptional profiling reveals functional dichotomy between human slan+non-classical monocytes and myeloid dendritic cells. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1055-1068.	3.3	40
85	Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1017-1034.	3.3	67
86	High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 51-61.	4.2	28
87	Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. <i>Radiology</i> , 2017, 282, 585-597.	7.3	111
88	In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 87.	4.8	43
89	The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. <i>Frontiers in Immunology</i> , 2017, 8, 631.	4.8	154
90	Comparative phenotypic and functional analysis of migratory dendritic cell subsets from human oral mucosa and skin. <i>PLoS ONE</i> , 2017, 12, e0180333.	2.5	15

#	ARTICLE	IF	CITATIONS
91	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0157830.	2.5	69
92	Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features. Immunology, 2016, 149, 111-121.	4.4	14
93	Highly specific and potently activating V $\beta$ 9V $\alpha$ 2-T cell specific nanobodies for diagnostic and therapeutic applications. Clinical Immunology, 2016, 169, 128-138.	3.2	29
94	Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells. Clinical Immunology, 2016, 168, 47-54.	3.2	21
95	Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Modern Pathology, 2016, 29, 753-763.	5.5	230
96	A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. British Journal of Cancer, 2016, 115, 940-948.	6.4	4
97	Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. , 2016, 4, 78.		56
98	Immune-competent human skin disease models. Drug Discovery Today, 2016, 21, 1479-1488.	6.4	39
99	Sensing of latent EBV infection through exosomal transfer of 5 $\beta$ pppRNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E587-96.	7.1	136
100	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. Oncoimmunology, 2016, 5, e1105431.	4.6	11
101	Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node. Cancer Immunology, Immunotherapy, 2016, 65, 405-415.	4.2	27
102	Apoptotic vesicles as tumor vaccine. Immunotherapy, 2016, 8, 5-8.	2.0	3
103	MUTZ-3 Langerhans Cell maturation and CXCL12 independent migration in reconstructed human gingiva. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 423-434.	1.5	14
104	TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. Oncotarget, 2016, 7, 67087-67100.	1.8	43
105	Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR. Oncotarget, 2016, 7, 5240-5257.	1.8	23
106	Umbilical cord blood stem cell derived NK cells as universal treatment for metastatic colorectal cancer using EGFR independent killing mechanisms.. Journal of Clinical Oncology, 2016, 34, e14525-e14525.	1.6	0
107	Allogeneic NK cells generated from cord blood as universal treatment for cervical cancer enabled by HLA independent killing mechanisms.. Journal of Clinical Oncology, 2016, 34, e14526-e14526.	1.6	0
108	CD141 Expressing Monocytes Show an Inflammatory Profile and Are Associated with Low-Risk Features in Myelodysplastic Syndromes. Blood, 2016, 128, 4298-4298.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. <i>Current Opinion in Oncology</i> , 2015, 27, 482-488.	2.4	31
110	Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials. , 2015, 3, .		0
111	A Human Cell Line Model for Interferon- $\gamma$ Driven Dendritic Cell Differentiation. <i>PLoS ONE</i> , 2015, 10, e0135219.	2.5	1
112	Phenotypic and Functional Properties of Human Steady State CD14 <sup>+</sup> and CD1a <sup>+</sup> Antigen Presenting Cells and Epidermal Langerhans Cells. <i>PLoS ONE</i> , 2015, 10, e0143519.	2.5	18
113	Hematopoietic Cancer Cell Lines Can Support Replication of Sabin Poliovirus Type 1. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	6
114	Gingiva Equivalents Secrete Negligible Amounts of Key Chemokines Involved in Langerhans Cell Migration Compared to Skin Equivalents. <i>Journal of Immunology Research</i> , 2015, 2015, 1-11.	2.2	33
115	Vaccination approach to anti-angiogenic treatment of cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 155-171.	7.4	22
116	High and Interrelated Rates of PD-L1+CD14 <sup>+</sup> Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 48-58.	3.4	95
117	MUTZ-3 derived Langerhans cells in human skin equivalents show differential migration and phenotypic plasticity after allergen or irritant exposure. <i>Toxicology and Applied Pharmacology</i> , 2015, 287, 35-42.	2.8	64
118	Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1241-1250.	4.2	98
119	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1271-1286.	4.2	161
120	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. <i>Clinical Immunology</i> , 2015, 158, 92-99.	3.2	2
121	Proteasome inhibitors as experimental therapeutics of autoimmune diseases. <i>Arthritis Research and Therapy</i> , 2015, 17, 17.	3.5	101
122	Arming oncolytic viruses to leverage antitumor immunity. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 959-971.	3.1	53
123	Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141 <sup>+</sup> Dendritic Cells and Enhanced Cross-Presentation. <i>Cancer Immunology Research</i> , 2015, 3, 495-505.	3.4	50
124	In situ Delivery of Antigen to DC-SIGN <sup>+</sup> CD14 <sup>+</sup> Dermal Dendritic Cells Results in Enhanced CD8 <sup>+</sup> T-Cell Responses. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2228-2236.	0.7	35
125	mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells. <i>Journal of Immunology</i> , 2015, 195, 2038-2045.	0.8	23
126	CD14 <sup>+</sup> macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?. <i>Oncolmmunology</i> , 2015, 4, e1009296.	4.6	21



#	ARTICLE	IF	CITATIONS
127	Differential capacity of human interleukin-4 and interferon- $\gamma$ monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1419-1427.	4.2	12
128	Response to Comment on "mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells". <i>Journal of Immunology</i> , 2015, 195, 5101-5102.	0.8	0
129	Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. <i>International Journal of Cancer</i> , 2015, 136, 127-137.	5.1	43
130	Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to $\gamma$ -T Cell Mediated Killing, Provided CLL-Derived $\gamma$ -T Cell Dysfunction Can be Reversed. <i>Blood</i> , 2015, 126, 2914-2914.	1.4	3
131	A novel combinatorial therapy using cytolytic NK cells and anti-EGFR moAb to improve the treatment of EGFR expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14017-e14017.	1.6	1
132	Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. <i>Oncotarget</i> , 2015, 6, 32484-32493.	1.8	48
133	Dendritic Cell Subsets in Bone Marrow and Peripheral Blood of Patients with Myelodysplastic Syndromes Display Numeric and Functional Defects. <i>Blood</i> , 2015, 126, 4109-4109.	1.4	0
134	$\gamma$ -T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. <i>Oncolimmunology</i> , 2014, 3, e955343.	4.6	1
135	In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity. <i>Oncolimmunology</i> , 2014, 3, e946360.	4.6	5
136	CD1d-Restricted Antigen Presentation by $\gamma$ -T Cells Requires Trogocytosis. <i>Cancer Immunology Research</i> , 2014, 2, 732-740.	3.4	19
137	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. , 2014, 2, 31.		92
138	Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1622-1632.	3.3	4
139	Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 560-575.	7.4	36
140	Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8 <sup>+</sup> T cell cross-priming. <i>European Journal of Immunology</i> , 2014, 44, 2415-2424.	2.9	52
141	Bispecific antibody platforms for cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 153-165.	4.4	78
142	Effects of Antigen-Expressing Immunostimulatory Liposomes on Chemotaxis and Maturation of Dendritic Cells In Vitro and in Human Skin Explants. <i>Pharmaceutical Research</i> , 2014, 31, 516-526.	3.5	3
143	Exploiting the CD1d-iNKT Cell Axis for Potentiation of DC-Based Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2014, 1139, 155-165.	0.9	5
144	Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. <i>Journal of Translational Medicine</i> , 2013, 11, 152.	4.4	12

#	ARTICLE	IF	CITATIONS
145	Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. <i>Immunotherapy</i> , 2013, 5, 859-868.	2.0	8
146	Antigen Targeting to Dendritic Cells for Cancer Immunotherapy. , 2013, , 147-171.		0
147	T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 245-256.	4.2	79
148	Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. <i>Experimental Hematology and Oncology</i> , 2013, 2, 2.	5.0	17
149	Procedures for the expansion of CD14+precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy. <i>Immunotherapy</i> , 2013, 5, 1183-1190.	2.0	2
150	Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14+ Cells at the Cross-Roads of Immune Activation and Suppression. <i>Frontiers in Immunology</i> , 2013, 4, 403.	4.8	30
151	Functional characterization of a STAT3-dependent dendritic cell-derived CD14 <sup>+</sup> cell population arising upon IL-10-driven maturation. <i>Oncolmmunology</i> , 2013, 2, e23837.	4.6	31
152	IL-21 in cancer immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e24522.	4.6	32
153	Intradermal Delivery of TLR Agonists in a Human Explant Skin Model: Preferential Activation of Migratory Dendritic Cells by Polyribosinic-Polyribocytidylic Acid and Peptidoglycans. <i>Journal of Immunology</i> , 2013, 190, 3338-3345.	0.8	34
154	Priming of PRAME- and WT1-specific CD8 <sup>+</sup> T cells in healthy donors but not in AML patients in complete remission. <i>Oncolmmunology</i> , 2013, 2, e23971.	4.6	15
155	Transcriptional Profiling of Human Dendritic Cell Populations and Models - Unique Profiles of In Vitro Dendritic Cells and Implications on Functionality and Applicability. <i>PLoS ONE</i> , 2013, 8, e52875.	2.5	107
156	Clinical and Immunological Results Of a Phase I/IIa Study Of Allogeneic Dendritic Cell (DC) Vaccination, An "off The shelf" Treatment To Prevent Or Delay Relapse In Elderly Patients With Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2651-2651.	1.4	5
157	IL-10 Conditioning of Human Skin Affects the Distribution of Migratory Dendritic Cell Subsets and Functional T Cell Differentiation. <i>PLoS ONE</i> , 2013, 8, e70237.	2.5	31
158	Allogeneic dendritic cell (DC) vaccination as an "off the shelf" treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3029-3029.	1.6	0
159	Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. <i>Oncolmmunology</i> , 2012, 1, 649-658.	4.6	62
160	Epstein-Barr Virus-Encoded BART1 Protein is a Decoy Receptor for Macrophage Colony Stimulating Factor and Interferes with Macrophage Differentiation and Activation. <i>Viral Immunology</i> , 2012, 25, 461-470.	1.3	26
161	Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> . 2012. 341. 174-182.	2.5	92
162	Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2012, 30, 567-570.	1.6	52

#	ARTICLE	IF	CITATIONS
163	Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 509-517.	10.7	390
164	Applying ceramic nanoporous microneedle arrays as a transport interface in egg plants and an ex-vivo human skin model. <i>Microelectronic Engineering</i> , 2012, 98, 659-662.	2.4	55
165	Preferential Langerhans cell differentiation from CD34 <sup>+</sup> precursors upon introduction of ABCG2 (BCRP). <i>Immunology and Cell Biology</i> , 2012, 90, 206-215.	2.3	10
166	CCL5 and CCL20 mediate immigration of Langerhans cells into the epidermis of full thickness human skin equivalents. <i>European Journal of Cell Biology</i> , 2012, 91, 765-773.	3.6	34
167	Adenovirus-Based Immunotherapy of Cancer: Promises to Keep. <i>Advances in Cancer Research</i> , 2012, 115, 147-220.	5.0	16
168	CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic. <i>Journal of Gene Medicine</i> , 2012, 14, 416-427.	2.8	22
169	Activated iNKT cells promote V $\beta$ 9V $\alpha$ 2-T cell anti-tumor effector functions through the production of TNF- $\alpha$ . <i>Clinical Immunology</i> , 2012, 142, 194-200.	3.2	16
170	Glycan-modified liposomes boost CD4 <sup>+</sup> and CD8 <sup>+</sup> T-cell responses by targeting DC-SIGN on dendritic cells. <i>Journal of Controlled Release</i> , 2012, 160, 88-95.	9.9	158
171	Feasibility of flowcytometric quantitation of immune effector cell subsets in the sentinel lymph node of the breast after cryopreservation. <i>Journal of Immunological Methods</i> , 2012, 375, 189-195.	1.4	7
172	Exposure of CD34 <sup>+</sup> precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 181-191.	4.2	18
173	The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma. <i>Current Topics in Microbiology and Immunology</i> , 2011, 351, 181-220.	1.1	15
174	Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. <i>Vaccine</i> , 2011, 29, 2313-2321.	3.8	18
175	Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. <i>Blood</i> , 2011, 118, 2502-2510.	1.4	90
176	Clinical experience with $\alpha$ -galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. <i>Clinical Immunology</i> , 2011, 140, 130-141.	3.2	87
177	Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 37-47.	4.2	14
178	High susceptibility of c-KIT <sup>+</sup> CD34 <sup>+</sup> precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 943-951.	4.2	6
179	Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. <i>Immunotherapy</i> , 2011, 3, 77-96.	2.0	25
180	Irritant-Induced Migration of Langerhans Cells Coincides with an IL-10-Dependent Switch to a Macrophage-Like Phenotype. <i>Journal of Investigative Dermatology</i> , 2011, 131, 418-425.	0.7	28

#	ARTICLE	IF	CITATIONS
181	Technical Advance: Langerhans cells derived from a human cell line in a full-thickness skin equivalent undergo allergen-induced maturation and migration. <i>Journal of Leukocyte Biology</i> , 2011, 90, 1027-1033.	3.3	72
182	Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine. <i>Cancer Research</i> , 2011, 71, 5827-5837.	0.9	31
183	Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34+precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. <i>Immunotherapy</i> , 2011, 3, 1051-1061.	2.0	8
184	Selective Transduction of Dendritic Cells in Human Lymph Nodes and Superior Induction of High-avidity Melanoma-reactive Cytotoxic T Cells by a CD40-targeted Adenovirus. <i>Journal of Immunotherapy</i> , 2010, 33, 706-715.	2.4	26
185	Monophosphoryl lipid A plus IFN $\gamma$ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1185-1195.	4.2	30
186	Attenuation of invariant Natural Killer T-cell anergy induction through intradermal delivery of $\beta$ -galactosylceramide. <i>Clinical Immunology</i> , 2010, 136, 364-374.	3.2	24
187	Epidermis $\rightarrow$ dermis migration of immature Langerhans cells upon topical irritant exposure is dependent on CCL2 and CCL5. <i>European Journal of Immunology</i> , 2010, 40, 2026-2034.	2.9	50
188	Comparison of a novel CXCL12/CCL5 dependent migration assay with CXCL8 secretion and CD86 expression for distinguishing sensitizers from non-sensitizers using MUTZ-3 Langerhans cells. <i>Toxicology in Vitro</i> , 2010, 24, 578-585.	2.4	43
189	Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. <i>Immunotherapy</i> , 2010, 2, 69-83.	2.0	22
190	Functional delivery of viral miRNAs via exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 6328-6333.	7.1	1,437
191	Apoptotic Blebs From Leukemic Cells as a Source of Tumor Associated Antigen for Monocyte-Derived Dendritic Cell Loading. <i>Blood</i> , 2010, 116, 3283-3283.	1.4	0
192	Expansion of AML Blasts Induces CD14 Expression and Facilitates Leukemic DC Development for Therapeutic Application In AML. <i>Blood</i> , 2010, 116, 2193-2193.	1.4	2
193	ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. <i>Journal of Leukocyte Biology</i> , 2009, 86, 1075-1087.	3.3	83
194	Unimpaired immune functions in the absence of Mrp4 (Abcc4). <i>Immunology Letters</i> , 2009, 124, 81-87.	2.5	12
195	A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. <i>Vaccine</i> , 2009, 27, 7116-7124.	3.8	44
196	The ABC of dendritic cell development and function. <i>Trends in Immunology</i> , 2009, 30, 421-429.	6.8	37
197	Selective Transduction of Mature DC in Human Skin and Lymph Nodes by CD80/CD86-targeted Fiber-modified Adenovirus-5/3. <i>Journal of Immunotherapy</i> , 2009, 32, 895-906.	2.4	14
198	Mutz-3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors. <i>Journal of Leukocyte Biology</i> , 2009, 87, 637-643.	3.3	30

#	ARTICLE	IF	CITATIONS
199	Absence of Granzyme B Positive Tumour-Infiltrating Lymphocytes in Primary Melanoma Excisional Biopsies is Strongly Associated with the Presence of Sentinel Lymph Node Metastasis. <i>Analytical Cellular Pathology</i> , 2009, 31, 407-413.	1.4	0
200	Maturation by Toll Like Receptor Ligand R848 Improves the Uptake of Apoptotic Leukemic Cells by Monocyte Derived Dendritic Cells.. <i>Blood</i> , 2009, 114, 2075-2075.	1.4	0
201	Functional PRAME Specific T Cells Can Be Cultured From CD8+ Cells From Healthy Donors but Not From Patients at First CR: Implications for Immunotherapeutic Strategies in AML.. <i>Blood</i> , 2009, 114, 4139-4139.	1.4	0
202	Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1569-1577.	4.2	167
203	Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T lymphocytes and preserved MHC class I antigen expression. <i>International Journal of Cancer</i> , 2008, 123, 609-615.	5.1	104
204	CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis. <i>European Journal of Immunology</i> , 2008, 38, 3050-3059.	2.9	109
205	The novel bispecific diabody $\hat{I}\pm CD40/\hat{I}\pm CD28$ strengthens leukaemic dendritic cell induced T cell reactivity. <i>British Journal of Haematology</i> , 2008, 142, 273-283.	2.5	8
206	Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1364-1373.	3.3	73
207	Transcriptional profiling of human skin-resident Langerhans cells and CD1a+dermal dendritic cells: differential activation states suggest distinct functions. <i>Journal of Leukocyte Biology</i> , 2008, 84, 143-151.	3.3	41
208	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5884-5892.	7.0	127
209	Inducing Antitumor T Cell Immunity: Comparative Functional Analysis of Interstitial Versus Langerhans Dendritic Cells in a Human Cell Line Model. <i>Journal of Immunology</i> , 2008, 180, 4540-4549.	0.8	43
210	Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 4532-4542.	7.0	114
211	A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. <i>Blood</i> , 2008, 112, 2353-2359.	1.4	48
212	Comparative Analysis of CD8+ t Cell Priming Efficiencies against a Panel of Leukemia-Associated HLA-A2 Restricted Epitopes Identifies PRAME as a Possible Vaccination Target in AML. <i>Blood</i> , 2008, 112, 5441-5441.	1.4	0
213	Identification and Characterization of ErbB-3-Binding Protein-1 as a Target for Immunotherapy. <i>Journal of Immunology</i> , 2007, 179, 2005-2012.	0.8	14
214	Leukemia-Specific T-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1BB Targeting. <i>Clinical Cancer Research</i> , 2007, 13, 307-315.	7.0	33
215	Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients. <i>Clinical Cancer Research</i> , 2007, 13, 2961-2969.	7.0	125
216	CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2007, 121, 1749-1755.	5.1	134

#	ARTICLE	IF	CITATIONS
217	Immunomodulation of the melanoma sentinel lymph node: A novel adjuvant therapeutic option. <i>Immunobiology</i> , 2006, 211, 651-661.	1.9	18
218	Constitutively Active STAT5b Induces Cytokine-Independent Growth of the Acute Myeloid Leukemia-Derived MUTZ-3 Cell Line and Accelerates Its Differentiation Into Mature Dendritic Cells. <i>Journal of Immunotherapy</i> , 2006, 29, 188-200.	2.4	17
219	In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1480-1490.	4.2	54
220	Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content. <i>Clinical Cancer Research</i> , 2006, 12, 2826-2833.	7.0	34
221	Dendritic Cells Require Multidrug Resistance Protein 1 (ABCC1) Transporter Activity for Differentiation. <i>Journal of Immunology</i> , 2006, 176, 5191-5198.	0.8	56
222	A CD34+human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+Langerhans cell precursor. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1337-1344.	3.3	61
223	A Postmigrational Switch among Skin-Derived Dendritic Cells to a Macrophage-Like Phenotype Is Predetermined by the Intracutaneous Cytokine Balance. <i>Journal of Immunology</i> , 2006, 176, 7232-7242.	0.8	59
224	Intradermal Delivery of Adenoviral Type-35 Vectors Leads to High Efficiency Transduction of Mature, CD8+ T Cell-Stimulating Skin-Emigrated Dendritic Cells. <i>Journal of Immunology</i> , 2006, 177, 2208-2215.	0.8	25
225	The Novel Bispecific Diabody $\hat{I}\pm$ CD40/ $\hat{I}\pm$ CD28 Strengthens Leukemic Dendritic Cell Induced T Cell Reactivity.. <i>Blood</i> , 2006, 108, 3710-3710.	1.4	0
226	High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. <i>Cancer Biology and Therapy</i> , 2005, 4, 289-294.	3.4	37
227	A Single-Component CD40-Targeted Adenovirus Vector Displays Highly Efficient Transduction and Activation of Dendritic Cells in a Human Skin Substrate System. <i>Molecular Pharmaceutics</i> , 2005, 2, 218-223.	4.6	21
228	Circulating $\hat{V}\pm$ 24+ $\hat{V}\pm$ 11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. <i>Clinical Immunology</i> , 2005, 114, 183-189.	3.2	36
229	Matched Skin and Sentinel Lymph Node Samples of Melanoma Patients Reveal Exclusive Migration of Mature Dendritic Cells. <i>American Journal of Pathology</i> , 2005, 167, 1301-1307.	3.8	30
230	Immunotherapy of Cancer by Dendritic Cell-Targeted Gene Transfer. , 2005, , 143-172.		2
231	Local Administration of Granulocyte/Macrophage Colony-stimulating Factor Increases the Number and Activation State of Dendritic Cells in the Sentinel Lymph Node of Early-Stage Melanoma. <i>Cancer Research</i> , 2004, 64, 8456-8460.	0.9	63
232	Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: clinical and biological concepts. <i>Clinical and Translational Oncology</i> , 2004, 6, 130-139.	2.4	0
233	Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 455-462.	4.2	35
234	CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. <i>Vaccine</i> , 2003, 21, 2268-2272.	3.8	55

#	ARTICLE	IF	CITATIONS
235	Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation. <i>Journal of Immunology</i> , 2002, 168, 4333-4343.	0.8	194
236	Up-Regulation of Drug Resistance-Related Vaults During Dendritic Cell Development. <i>Journal of Immunology</i> , 2002, 168, 1572-1578.	0.8	47
237	Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors. <i>Journal of Immunology</i> , 2002, 169, 5322-5331.	0.8	66
238	MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+precursors. <i>Blood</i> , 2002, 100, 701-703.	1.4	138
239	Sampling Tumor-Draining Lymph Nodes for Phenotypic and Functional Analysis of Dendritic Cells and T Cells. <i>American Journal of Pathology</i> , 2002, 161, 19-26.	3.8	39
240	Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. <i>Journal of Leukocyte Biology</i> , 2002, 72, 321-9.	3.3	34
241	Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. <i>International Journal of Cancer</i> , 2000, 88, 92-98.	5.1	79
242	Human natural killer T cells acquire a memory-activated phenotype before birth. <i>Blood</i> , 2000, 95, 2440-2442.	1.4	94
243	Human natural killer T cells acquire a memory-activated phenotype before birth. <i>Blood</i> , 2000, 95, 2440-2442.	1.4	6
244	Cancer vaccine strategies get bigger and better. <i>Nature Medicine</i> , 1999, 5, 1124-1125.	30.7	21
245	Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. <i>Journal of Immunology</i> , 1999, 162, 6378-83.	0.8	128